Plain-English translation of NCT06474806 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging agent called that helps doctors see which cancer cells are most active and aggressive. The medication is injected into your bloodstream and then shows up on a special PET scanner, allowing doctors to visualize your prostate cancer without needing to do as many biopsies. The goal is to see if this imaging test can safely and accurately measure how fast your cancer might grow.
Many men with low-grade prostate cancer are monitored through repeated biopsies, which are uncomfortable and carry small risks of infection and side effects. This trial exists to see whether the new imaging approach could give doctors the same important information with just a scan, potentially sparing patients from having to undergo multiple biopsies.
You likely qualify if…
You likely don't qualify if…
If you're in Part 1 of the study, you'll receive two imaging scans 8 days apart—each involving an injection of the medication followed by time in a PET scanner to take pictures of your prostate. If you're in Part 2, you'll have one imaging scan with the same process. Before and after each scan, you'll have routine tests including blood work, urine samples, heart function checks, and health evaluations to make sure the medication is safe.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Denmark
Germany